- Home
- HRTX vs AARD Comparison
HRTX vs AARD Comparison
Compare HRTX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- AARD
- Stock Information
- Founded
- HRTX 1983
- AARD 2017
- Country
- HRTX United States
- AARD United States
- Employees
- HRTX N/A
- AARD N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- AARD Health Care
- Exchange
- HRTX Nasdaq
- AARD Nasdaq
- Market Cap
- HRTX 203.5M
- AARD 231.9M
- IPO Year
- HRTX 1987
- AARD 2025
- Fundamental
- Price
- HRTX $1.11
- AARD $9.79
- Analyst Decision
- HRTX Strong Buy
- AARD Strong Buy
- Analyst Count
- HRTX 2
- AARD 8
- Target Price
- HRTX $4.50
- AARD $30.63
- AVG Volume (30 Days)
- HRTX 2.1M
- AARD 168.1K
- Earning Date
- HRTX 11-04-2025
- AARD 11-13-2025
- Dividend Yield
- HRTX N/A
- AARD N/A
- EPS Growth
- HRTX N/A
- AARD N/A
- EPS
- HRTX N/A
- AARD N/A
- Revenue
- HRTX $155,097,000.00
- AARD N/A
- Revenue This Year
- HRTX $10.62
- AARD N/A
- Revenue Next Year
- HRTX $12.99
- AARD N/A
- P/E Ratio
- HRTX N/A
- AARD N/A
- Revenue Growth
- HRTX 12.60
- AARD N/A
- 52 Week Low
- HRTX $1.04
- AARD $4.88
- 52 Week High
- HRTX $2.68
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- HRTX 39.29
- AARD 39.60
- Support Level
- HRTX $1.09
- AARD $9.75
- Resistance Level
- HRTX $1.14
- AARD $10.94
- Average True Range (ATR)
- HRTX 0.07
- AARD 0.86
- MACD
- HRTX 0.00
- AARD -0.01
- Stochastic Oscillator
- HRTX 27.08
- AARD 20.28
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.